acute biphenotypic leukemia (Cancer)
Information
- Disease name
- acute biphenotypic leukemia
- Disease ID
- DOID:9953
- Description
- "An acute leukemia that is characterized by the occurrence of more than one type of leukemia at the same time resulting from either the occurrence of blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens." [url:https\://www.ncbi.nlm.nih.gov/pubmed/29021517]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT02159495 | Active, not recruiting | Phase 1 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | December 15, 2015 | December 15, 2024 |
| NCT02220985 | Active, not recruiting | Phase 2 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | February 3, 2015 | April 1, 2025 |
| NCT01804101 | Completed | N/A | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia | May 7, 2013 | January 10, 2017 |
| NCT01858740 | Completed | Phase 2 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | April 10, 2014 | July 30, 2023 |
| NCT01951885 | Completed | Phase 3 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | July 7, 2014 | August 11, 2021 |
| NCT02044796 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | January 23, 2014 | April 16, 2018 |
| NCT02135874 | Completed | Phase 2 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | October 27, 2014 | February 21, 2023 |
| NCT02529813 | Completed | Phase 1 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | December 16, 2015 | November 8, 2021 |
| NCT00796068 | Completed | Phase 2 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | February 24, 2009 | December 14, 2021 |
| NCT01690520 | Completed | Phase 2 | Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes | December 11, 2012 | May 29, 2020 |
| NCT02397720 | Completed | Phase 2 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | April 7, 2015 | October 9, 2023 |
| NCT02728050 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 1, 2016 | April 4, 2023 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT03267186 | Completed | Phase 2 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | September 12, 2017 | April 30, 2021 |
| NCT03683433 | Recruiting | Phase 2 | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | September 18, 2018 | September 20, 2025 |
| NCT03779854 | Recruiting | Phase 2 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | August 29, 2019 | December 31, 2025 |
| NCT03399773 | Recruiting | Phase 2 | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | May 10, 2022 | June 30, 2026 |
| NCT02115295 | Recruiting | Phase 2 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | May 19, 2014 | May 31, 2026 |
| NCT04128501 | Recruiting | Phase 2 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | May 5, 2020 | December 31, 2026 |
| NCT02727803 | Recruiting | Phase 2 | Personalized NK Cell Therapy in CBT | May 19, 2016 | May 31, 2025 |
| NCT05589896 | Recruiting | Phase 1/Phase 2 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | March 30, 2024 | August 2025 |
| NCT04797767 | Suspended | Phase 1 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | February 4, 2022 | December 31, 2024 |
| NCT03326921 | Suspended | Phase 1 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | February 23, 2018 | July 16, 2028 |
| NCT02399917 | Terminated | Phase 2 | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | April 20, 2015 | July 12, 2018 |
| NCT03195010 | Terminated | Phase 2 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | June 9, 2017 | December 21, 2018 |
| NCT01028716 | Terminated | Phase 2 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | May 19, 2010 | October 7, 2021 |
| NCT01619761 | Unknown status | Phase 1 | NK Cells in Cord Blood Transplantation | May 3, 2013 | November 2021 |
| NCT05170828 | Withdrawn | Phase 1 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | September 2022 | November 2024 |
| NCT03739606 | Withdrawn | Phase 2 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | October 20, 2020 | October 20, 2020 |
- Disase is a (Disease Ontology)
- DOID:12603
- Cross Reference ID (Disease Ontology)
- ICD10CM:C95.0
- Cross Reference ID (Disease Ontology)
- ICDO:9805/3
- Cross Reference ID (Disease Ontology)
- MESH:D015456
- Cross Reference ID (Disease Ontology)
- NCI:C4673
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:128818009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023464
- Exact Synonym (Disease Ontology)
- mixed phenotype acute leukemia